Canada's drug pricing agency is contemplating significant changes to how it will apply new regulations aimed at lowering costs, Reuters has learned, as drugmakers unhappy with the policy delay introducing new medicines in the country and blame it for job cuts.
In response, Swiss drugmaker Roche last month withdrew its immunotherapy Tecentriq from evaluation as a treatment for breast cancer, citing"significant uncertainty and complexity" around the new regulation. Merck & Co in November said it would cut 145 jobs, 30per cent of its Canadian staff, blaming the new policy.
PMPRB Executive Director Doug Clark told Reuters companies could be given an 18-month grace period to comply with parts of the regulation, and that cost-effectiveness measures may be applied to fewer treatments. The PMPRB said threats by companies to pull products when faced with price controls in Germany in 2011 led to few withdrawals.
Innovative Medicines Canada, the industry's main lobby group, said at least seven drug launches have been delayed over the new regulations since August, but declined to identify them.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »